African Vaccine Manufacturing Accelerator (AVMA)
What is AVMA?
The African Vaccine Manufacturing Accelerator (AVMA) is a financing mechanism established to make up to US$ 1.2 billion available over ten years commencing with AVMA’s launch in June 2024 to accelerate the expansion of commercially viable vaccine manufacturing in Africa.
AVMA offers a ‘pull financing mechanism’ by providing downstream incentives to manufacturers to help offset initial costs of development and production.
The instrument was approved by the Gavi Board in December 2023 and launched in June 2024, following a design process conducted over nearly two years of close collaboration between Gavi, the African Union and the Africa Centres for Disease Control and Prevention (Africa CDC), with extensive consultations with partners, donors, industry, civil society and other stakeholders.
You might also like...
